Circulating cytokines in active polymyalgia rheumatica

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 263-269

  Alvarez Rodriguez L ^a   Lopez Hoyos, M ^a   Mata, C ^b   Jose Marin, M ^a   Calvo Alen, J ^b   Blanco, R ^a   Aurrecoechea, E ^b   Ruiz Soto, M ^a   Martinez Taboada V M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL SIERRALLANA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD LEVEL; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; SUPERNATANT; T LYMPHOCYTE; TH1 CELL;

AGED; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; POLYMYALGIA RHEUMATICA; PROSPECTIVE STUDIES; TH1 CELLS; TH2 CELLS;

EID: 73449087360     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.103663     Document Type: Article

References (33)

1. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002;347:261-71.
2. González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased ESR: a more benign syndrome. Arch Intern Med 1997;157:317-20.
3. Chuang T-Y, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
4. Martinez-Taboada VM, Alvarez L, Ruiz-Soto M, et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-20.
5. Straub RH, Gluck T, Cutolo M, et al. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumor necrosis factor) in polymyalgia rheumatica. Rheumatology 2000;39:624-31.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
8. Corrigal VM, Dolan AL, Dasgupta B, et al. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica as predictors of disease remission and steroid withdrawal. Br J Rheumatol 1997;36:976-80.
9. Uddhammar A, Sundqvist KG, Ellis B, et al. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:766-9.
10. Cutolo M, Straub RH, Foppiani L, et al. Adrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol 2002;29:748-56.
11. Cutolo M, Montecucco CM, Covagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006;63:1438-43.
12. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns distinguish polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
13. Straub RH, Herfarth HH, Rinkes B, et al. Favorable role of interleukin 10 in patients with polymyalgia rheumatica. J Rheumatol 1999;26:1318-25.
14. Caplanne D, Le Parc JM, Alexandre JA. Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1996;55:403-4.
15. Tellus M, Byron K, Sachthep S, et al. Cytokines in polymyalgia rheumatica. Arthritis Rheum 1996;39:1264-5.
16. Straub RH, Georgi J, Helmke K, et al. In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers. Rheumatology 2002;41:423-9.
17. Pountain G, Hazleman B, Cawston TE. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol 1998;37:797-8.
18. Hacker UT, Erhardt S, Tschöp K, et al. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1b after live yellow fever vaccination. Clin Exp Immunol 2001;125:465-9.
19. Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
20. Boiardi L, Salvarani C, Timms JM, et al. Interleukin-1 cluster and tumor necrosis factor-a gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:675-81.
21. Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M, et al. Interleukin-1RN gene polymorphisms in elderly patients with rheumatoid inflammatory chronic conditions: association of IL-1RN*2/2 genotype with polymyalgia rheumatica. Hum Immunol 2009;70:49-54.
22. Walker D, Jason J, Wallace K, et al. Spontaneous cytokine production and its effect on induced production. Clin Diagn Lab Immunol 2002;9:1049-56.
23. Jason J, Archibald LK, Nwanyanwu OC, et al. Comparison of serum and cell-specific cytokines in humans. Clin Diagn Lab Immunol 2001;8:1097-103.
24. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
25. Bennet L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
26. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85.
27. Prussin C, Metcalfe DD. Detection of intracytoplasmatic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995;188:117-28.
28. Boiardi L, Casali B, Farnetti E, et al. Interleukin-10 promoter polymorphisms in giant-cell arteritis. Arthritis Rheum 2006;54:4011-7.
29. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000;120:518-25.
30. Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2-and interferon-c-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998;39:996-1004.
31. Johansen HK, Hougen HP, Rygaard J, et al. Interferon-gamma treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996;103:212-8.
32. Moser C, Johansen HK, Song Z, et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 1997;105:838-42.
33. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:998-1006.